InCarda raises $30M to reimagine afib treatment with drug-device combo

Flecainide has been around to treat atrial fibrillation since the '80s, but Grace Colón, CEO of InCarda Therapeutics, thinks it needs a face-lift. Armed with $30 million in venture funding, InCarda hopes to make the drug available as an at-home inhalable treatment for patients in the early stages of the disease.